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Cell surface receptors are the major pathways for the transmission 
of information from outside to inside cells. The major classes of 
receptors are the enzymatically active protein tyrosine kinase and 
protein serine/threonine kinases and the non-enzymatically active 
Seven Transmembrane G Protein Coupled Receptors (GPCR). GPCRs 
are the largest class of receptors and provide the greatest number of 
targets for therapeutic agents with drugs such as Angiotensin Receptor 
Blockers (ARBs) being amongst the most efficacious and relatively safe 
drugs in cardiovascular medicine. 
Receptors utilise signalling pathways which most usually result in 
altered gene transcription and modifications of cellular phenotype and 
function. These signalling pathways can intersect and interact within 
the cell to enhance or negate the relevant responses in a phenomenon 
known as “cross talk” [1]. However, the interactions can also be at the 
level that one receptor interacts with another receptor in a phenomenon 
known as (receptor) transactivation [2]. GPCRs have linear signalling 
pathways involving the propagation of signals via second messengers 
such as phospholipase  C, adenylcyclase and phosphoinositide-3-
kinase, but two decades ago it was additionally discovered that cognate 
ligand activation of a GPCR could also lead to transactivation of Protein 
Tyrosine Kinase Receptors (PTKRs) [3]. A specific example involves 
the transactivation of the Epidermal Growth Factor Receptor (EGFR) 
by the GPCR agonist’s thrombin, Lysophosphatidic Acid (LPA) and 
Endothelin-1 (ET-1) in Rat-1 fibroblasts [3]. Linear GPRC signalling 
produces relatively rapid responses (sec or min); an example would be 
the angiotensin II interaction with its receptor leading to activation of 
phospholipase C and the generation of inositol 1,4,5-trisphosphate and 
the release of calcium ions from the endoplasmic reticulum leading 
to the contraction of a blood vessel [4]. Angiotensin  II or thrombin 
signalling via this linear pathway in cells in the Go stage of the cell cycle 
is not usually sufficient to produce a mitogenic response [5]. However, 
thrombin can also activate its receptor leading to transactivation 
of a PTKR such as the EGFR and this leads to the generation of the 
mitogenic precursor of phosphorylated p38 which follows its cascade 
to produce a full mitogenic response in vascular smooth muscle cells 
[6]. Studies over the last two decades have revealed that the major 
two pathways through which this transactivation occurs are ligand 
dependent and ligand independent. Ligand dependent transactivation, 
as its name suggests, involves the cleavage and liberation of a PTKR 
ligand, typically via a cell surface Matrix-Metalloproteinases (MMPs), 
that then follows on to activate the PTKR in an autocrine/paracrine 
manner. The most well characterised example of this includes the 
activation of MMPs, leading to the liberation of Heparin Binding-
EGF and subsequent ligand mediated receptor activation [7]. As 
this mechanism passes through the membrane three times before 
receptor activation, it is also referred to as ‘triple membrane passing’ 
transactivation. The second mode of GPCR mediated transactivation is 
devoid of ligand involvement, instead, the GPCR activates intracellular 
kinases such as Src, which directly phosphorylate the intracellular 
autophosphorylation sites of the PTKR, leading to activation [8]. 
Receptor transactivation greatly expands the repertoire of cellular 
responses associated with activation of the GPCR. Until recently this 
phenomenon of GPCR receptor transactivation has been restricted 
to members of the protein tyrosine kinase family including receptors 
for EGF, PDGF, IGF-1 and FGF [3,9-11]. However, there have now 
been several reports, including from our own laboratory, that GPRCs 
can transactivate members of the protein serine/threonine kinase 
receptor family, specifically those of the Transforming Growth Factor 
(TGF)-β superfamily. In this case the interaction of a cell with a GPCR 
agonist results in the slightly delayed production of phosphorylated 
Smad transcription factors (namely, phosphoSmad2) which are the 
immediate downstream products resulting from the activation of the 
Type I TGF-β receptor (TβRI) which possess serine/threonine kinase 
activity and is known also as Activin-like kinase 5 (Alk5) (12-15). The 
reported examples of this phenomena are the transactivation of Alk5 
by thrombin and ET-1 in human vascular smooth muscle cells [12,13], 
and by thrombin and LPA in mouse lung epithelial cells [14,15], as 
well as the transactivation of the BMP receptor (part of the TGF-β 
superfamily) by serotonin in porcine and human aortic smooth muscle 
cells. The phenomenon has been described in detail to implicate the 
involvement of both the GPCR and Alk5. Mechanistically, data shows 
that the transactivation involves the small GTP binding protein 
RhoA and hence ROCK, the cytoskeleton and cell surface integrin 
[14,15]. Based on this data our current speculation is that the GPCR 
ligand interacts with the cognate GPCR to activate RhoA/ROCK, 
modifying the cytoskeleton which in turn mechanically perturbs the 
cell membrane leading to the opening of the Large Latent Complex 
(LLC) [16]. The LLC which is embedded in the extracellular matrix, 
encases the TGF-β ligand; this leads to the ‘presentation’ of the TGF-β 
as the cognate ligand (still within the LLC) to Alk5 and hence allowing 
for Alk5-mediated serine/threonine phosphorylation of the regulatory 
Smad transcription factors [17]. Perhaps due to this mechanism 
and restricted site specific interaction between the active TGF-β in 
the LLC and its receptors, the transactivation response (increase 
in phosphoSmad2) has so far been seen to be of lower magnitude 
compared to the response arising from the introduction of exogenous 
free active TGF-β. The transactivation response is functionally active 
as evidenced in two ways. Firstly, the phosphoSmad2 generated by this 
pathway in human vascular smooth muscle cells translocates and can 
be identified in the cell nucleus. Secondly, phosphoSmad2 produces 
functional responses such as the stimulation of proteoglycan synthesis 
[12,13]. In our own work we have demonstrated that this thrombin 
receptor GPCR (Protease Activated Receptor 1) to Alk5transactivation 
pathway leads to the stimulation of the synthesis of the core protein for 
the small leucine rich lipid binding proteoglycan, biglycan as well as 
activation of the Golgi apparatus and the synthesis of hyperelongated 
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glycosaminoglycan (GAG) chains on the biglycan [12]. Others have 
shown that in mouse lung epithelial cells, the transactivation of Alk5 
by thrombin and LPA is an important event in lung injury. Specifically, 
interference of this pathway significantly protects mice from bleomycin 
induced lung injury and oedema [14,15].
GPCRs are thus especially promiscuous in their ability to 
transactivate at least some members of both of the major kinase 
families of cell surface receptors, these being protein tyrosine kinase 
and protein serine/threonine kinase receptors. This is not a question 
of “everything activates everything” because at least in the situation 
of one major pathway of GPCR transactivation of Alk5, the pathway 
that would represent reverse transactivation being the generation of 
IP3, TGF-β does not transactivate the thrombin GPCR, PAR-1 as no 
increase at all in IP3 is observed when cells are treated with TGF-β 
[12]. The full implication of this extension to the paradigm of GPCR 
transactivation signalling is not yet clear. Undoubtedly, the extent 
of physiological and potentially pathological responses to GPCRs is 
increased – whether or not this makes it easier or more difficult to 
address therapeutically is the major question. There is a need to identify 
the exact involvement of GPCRs, protein tyrosine kinase and protein 
serine/threonine kinases in each pathological condition and then 
to determine if a point of therapeutic intervention can be identified. 
Clearly, more work is required to identify the full range of partners 
involved in GPCR to protein serine/threonine kinase transactivation 
and also the mechanism(s) of these transactivation pathways. 
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